6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistance

Basit Öğe Kaydı
dc.authoridRasul, Azhar/0000-0001-9669-7364
dc.authoridShah, Muhammad Ajmal/0000-0003-3471-184X
dc.authoridAsrar, Mudassir/0000-0001-5190-6169
dc.authoridZahoor, Ameer Fawad/0000-0003-2127-8848
dc.authoridSelamoglu, Zeliha/0000-0001-9056-6435
dc.authoridHUSSAIN, Ghulam/0000-0001-9090-7789
dc.contributor.authorSarfraz, Iqra
dc.contributor.authorRasul, Azhar
dc.contributor.authorHussain, Ghulam
dc.contributor.authorShah, Muhammad Ajmal
dc.contributor.authorZahoor, Ameer Fawad
dc.contributor.authorAsrar, Muhammad
dc.contributor.authorSelamoglu, Zeliha
dc.date.accessioned2024-11-07T13:35:17Z
dc.date.available2024-11-07T13:35:17Z
dc.date.issued2020
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractReprogrammed metabolism is key biochemical characteristic of malignant cells, which represents one of the emerging hallmarks of cancer. Currently, there is rising contemplation on oxidative pentose phosphate pathway (PPP) enzymes as potential therapeutic hits due to their affiliation with tumor metabolism. 6-Phosphogluconate dehydrogenase (6PGD), third oxidative decarboxylase of PPP, has received a great deal of attention during recent years due to its critical role in tumorigenesis and redox homeostasis. 6PGD has been reported to overexpress in number of cancer types and its hyperactivation is mediated through post-transcriptional and post-translational modifications by YTH domain family 2 (YTHDF2), Nrf2 (nuclear factor erythroid 2-related factor 2), EGFR (epidermal growth factor receptor) and via direct structural interactions with ME1 (malic enzyme 1). Upregulated expression of 6PGD provides metabolic as well as defensive advantage to cancer cells, thus, promoting their proliferative and metastatic potential. Moreover, enhanced 6PGD expression also performs key role in development of chemoresistance as well as radiation resistance in cancer. This review aims to discuss the historical timeline and cancer-specific role of 6PGD, pharmacological and genetic inhibitors of 6PGD and 6PGD as prognostic biomarker in order to explore its potential for therapeutic interventions. We anticipate that targeting this imperative supplier of NADPH might serve as tempting avenue to combat the deadly disease like cancer.
dc.description.sponsorshipISESCO Research Grant [3620]; NRPU, HEC, Pakistan [8381]
dc.description.sponsorshipISESCO Research Grant, Grant/Award Number: 3620; NRPU, HEC, Pakistan, Grant/Award Number: 8381
dc.identifier.doi10.1002/biof.1624
dc.identifier.endpage562
dc.identifier.issn0951-6433
dc.identifier.issn1872-8081
dc.identifier.issue4
dc.identifier.pmid32039535
dc.identifier.scopus2-s2.0-85079372817
dc.identifier.scopusqualityQ1
dc.identifier.startpage550
dc.identifier.urihttps://doi.org/10.1002/biof.1624
dc.identifier.urihttps://hdl.handle.net/11480/16436
dc.identifier.volume46
dc.identifier.wosWOS:000512138000001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofBiofactors
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subject6PGD
dc.subjectpentose phosphate pathway
dc.subjecttherapeutic target
dc.subjecttumor metabolism
dc.title6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistance
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu